Ertugliflozin (PF 04971729)

CAS : 1210344-57-2

Ref. 3D-FE137670

Informations sur le produit

• Nom: Ertugliflozin (PF 04971729)
• Synonymes: (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol, 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose, 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-<span class="text-smallcaps">L</span>-idopyranose, Cc-212, Mk 8835, Pf 04971729-00, Pf-04971729, β-<span class="text-smallcaps">L</span>-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-
• CAS: 1210344-57-2

Description

Ertugliflozin is a novel, selective, and potent inhibitor of SGLT2. It is being developed for the treatment of type 2 diabetes and associated conditions such as hypertension, dyslipidemia and cardiovascular complications. Ertugliflozin selectively inhibits the renal glucose transporter SGLT2 to reduce urinary glucose excretion. In clinical trials ertugliflozin has been shown to significantly lower HbA1c levels in patients with type 2 diabetes mellitus. The drug was well tolerated in clinical trials with no clinically relevant adverse events observed. This agent has also been shown to decrease blood pressure in patients with type 2 diabetes mellitus and normotensive subjects.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 436.88 g/mol
• Formule: C₂₂H₂₅ClO₇
• Degré de pureté: Min. 96 Area-%
• Couleur/Forme: White Off-White Powder